Clinical Trial Research
BioVascular, Inc. Merges with Revitus and Acquires First-In-Class Platelet Count Reducer
Published in Drug Week, September 28th, 2007
BioVascular, Inc., a company focused on developing therapies targeting platelet-mediated diseases, announced that it has merged with Revitus, a privately-held company developing a first-in-class platelet count reducer, BVI-007. The announcement came as the first subject was dosed in a Phase Ia clinical trial of BVI-007, a thrombopoeitin antagonist that reduces platelet production without impacting platelet function. BVI-007 is being developed for the prevention of myocardial infarction, thrombotic stroke and death in patients who have had a previous cardiovascular event.
"BioVascular and Revitus were both focusing on novel therapeutics for platelet-mediated diseases,"...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
Source: Drug Week (2007-09-28)
More Articles from Drug Week
- Adverse Drug Reactions
Study shows adverse drug events reported to the FDA have significantly increased - Arthritis
Study identifies genetic risk factor for rheumatoid arthritis, lupus - Biomedicine
Study Sheds Light on Role of Vitamin E in Heart Disease Prevention - Blood Safety
Scientists, physicians present latest findings in 'personalized' cancer treatment and prevention - Boston University
BUSM, BMC adopt strict policy on interactions between clinicians and industry - Breast Cancer
New clues to breast cancer development in high-risk women - More from this issue of Drug Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
